Deliver Your News to the World

Australian Parkinsonís Mission Integrates Breakthrough Genomics and Clinical Trials

he Australian Parkinsonís Mission, an innovative program combining clinical trials with genomics research for people with Parkinsonís, has received $30 million in Federal Government funding, the most significant investment in Australian Parkinsonís research.

Australia – WEBWIRE

The funding, announced by Federal Minister for Health, The Hon. Greg Hunt MP, will enable the Australian Parkinsonís Mission to identify desperately needed disease modifying drugs with the potential to slow the progression of Parkinsonís.

ďWeíre thrilled to announce $30 million over five years in funding from the Medical Research Future Fund. The Australian Parkinsonís Mission aligns with many of the priorities of the Medical Research Future Fund which includes addressing areas of unmet need, genomics and developing new treatments from drug repurposing,Ē says The Hon. Greg Hunt, MP.

ďThere are approximately 100,000 Australians living with Parkinsonís. Currently, there are no treatments that can slow, stop or cure the disease, and no ways for us to detect and diagnose the disease early. The Australian Parkinsonís Mission is a big step towards identifying the underlying cause of this devastating disease, treatments that stop the disease progressing and, ultimately, a cure.Ē

The Australian Parkinsonís Mission will test repurposed drugs in a world-first in Parkinsonís clinical trial design, which means effective treatments can be identified and fast tracked to people with the disease. Sequencing the genome of each patient, the Australian Parkinsonís Mission will establish a first step toward personalised medicine for Parkinsonís patients and will drive drug discovery in the future.

The Mission is an Australian-led international collaboration, developed by the Garvan Institute of Medical Research, Shake It Up Australia Foundation, Parkinsonís Australia, The Cure Parkinsonís Trust and The Michael J. Fox Foundation for Parkinsonís Research.

Head of the Neurodegeneration and Neurogenomics Program at the Garvan Institute, Associate Professor Antony Cooper, says, ďThe Australian Parkinsonís Mission employs an entirely new design for Parkinsonís. The findings from our clinical trials will be integrated with analyses of patientsí genomic information and biomarkers -- naturally occurring measurable indicators of a disease. This will help us identify the right drug for the right patient to halt this disease.Ē

CEO of Shake It Up Australia, Clyde Campbell, who was diagnosed with Parkinsonís in 2009, says, ďThis five year program includes multiple clinical trials of potentially disease modifying drugs and treatments across Australia and will include many hundreds of patients. Itís going to have a substantial impact on identifying effective treatments and fast tracking them to people with the disease.Ē

Neurologists, Professor Simon Lewis (National Trials Lead) and Associate Professor John OíSullivan (Uni Qld Trials Lead), say, ďDespite substantial efforts, weíre still no closer to better treatments against disease progression or diagnostics for Parkinsonís. This is a multifaceted approach with international experts to address the primary unmet need in Parkinsonís globally.Ē

Director of Research and Development at The Cure Parkinsonís Trust, Dr Richard Wyse says, ďThe Australian Parkinsonís Mission will initially test the effectiveness of four repurposed drugs from The Cure Parkinsonís Trustís international Linked Clinical Trials programme which have been evaluated by a committee of international Parkinsonís experts, to prioritise drugs with the potential to slow or stop Parkinsonís disease. With thanks to the Australian Government for its visionary support in this ground-breaking and unified approach to tackling Parkinsonís in Australia and around the world.Ē

Senior Vice President, Research Programs at The Michael J. Fox Foundation for Parkinsonís Research, Dr Brian Fiske, said, ďAs a global leader in funding research and therapeutic development for Parkinsonís disease, we are thrilled that the Australian government is supporting this important mission. It has the potential to advance precision medicine and improve treatment for people with Parkinsonís worldwide.Ē

CEO of Parkinsonís Australia, Steve Sant says, ďThis represents the most significant investment in Parkinsonís research in Australian history. We applaud the Government for their innovative and forward-thinking actions to support this Australian-led international effort.Ē

The Mission also collaborates with Associate Professor Vikram Khurana at Brigham and Womenís Hospital and the Harvard Stem Cell Institute and Assistant Professor, Jian Peng at the University of Illinois at Urbana-Champaign.

The Australian Parkinsonís Mission was made possible by early philanthropic support from Geoff and Dawn Dixon, David and Helen Baffsky, Dr Richard Balanson and Dawn Talbot and the Shake It Up Australia Foundation.

( Press Release Image: )


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.